SCHEMBL5359293

SCHEMBL5359293

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.55
EGFR P00533 3/20 0.55
ERBB2 P04626 3/20 0.55
IGF1R P08069 1/20 0.55
MAP1LC3B Q9GZQ8 3/20 0.53
LRRK2 Q5S007 3/20 0.53
PSEN1 P49768 1/20 0.53
PSEN2 P49810 1/20 0.53
APH1B Q8WW43 1/20 0.53
NCSTN Q92542 1/20 0.53
APH1A Q96BI3 1/20 0.53
PSENEN Q9NZ42 1/20 0.53
NTRK1 P04629 1/20 0.53
ARAF P10398 1/20 0.53
PIM1 P11309 1/20 0.53
BRAF P15056 1/20 0.53
CSNK2A1 P68400 1/20 0.53
PIM3 Q86V86 1/20 0.53
SIRT2 Q8IXJ6 1/20 0.53
SIRT1 Q96EB6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365058 0.93 ERBB2 (0.64) RAF1EGFRERBB2IGF1RLRRK2
SCHEMBL5369480 0.89 ERBB2 (0.56) RAF1EGFRERBB2IGF1RLRRK2
SCHEMBL5365593 0.89 ERBB2 (0.55) RAF1EGFRERBB2IGF1RLRRK2
SCHEMBL5364961 0.88 MAP1LC3B (0.67) RAF1EGFRMAP1LC3BLRRK2PSEN1
SCHEMBL5362073 0.87 ERBB2 (0.70) RAF1EGFRERBB2IGF1RLRRK2
SCHEMBL5365035 0.86 ERBB2 (0.53) RAF1EGFRERBB2IGF1RLRRK2
SCHEMBL5369768 0.85 MOGAT2 (0.51) RAF1EGFRERBB2IGF1RMAP1LC3B
SCHEMBL5363069 0.85 SRC (0.51) EGFRERBB2IGF1RLRRK2NTRK1
SCHEMBL5368923 0.83 ERBB2 (0.59) EGFRERBB2IGF1RLRRK2NTRK1
SCHEMBL5358229 0.83 LRRK2 (0.64) RAF1EGFRMAP1LC3BLRRK2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK RAF1 245/4885EGFR 286/4885ERBB2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.